Navigation Links
Medbox Executes $6 Million Equity Transaction with Private Investment Firm
Date:2/19/2013

HOLLYWOOD, Calif., Feb. 19, 2013 /PRNewswire/ -- Medbox, Inc. (OTC Markets: MDBX) (www.medboxinc.com), announced that the company has executed a $6 million equity transaction with a private investment firm involving a restricted stock purchase directly from the company at market rate as of January 17, 2013 for $5 million and the remaining $1 million stock purchase at a discount to market. The shares issued are considered a long-term investment for the firm that specializes in funding up-and-coming companies. The investment firm has made an initial payment to Medbox and is scheduled to complete funding of the transaction by May 2013.  

The instant transaction, along with other opportunities currently being investigated by Medbox management, provides alternative acquisition funding sources in lieu of the company's founder selling affiliate shares into the market in order to fund expansion. To date, the company reports that the founder has not liquidated any shares into the public market. In addition, based on advice from counsel, affiliate shares cannot be sold publicly for 90 days after the company files its Form 10 with the SEC to become fully reporting. With the Form 10 on pace to being filed next month, the company has decided to seek out more traditional funding sources in lieu of founder funded expansion.

"Although we have an aggressive acquisition schedule for this year, the $6 million equity transaction, other viable transactions that have been presented to the company, and the company's earnings, will allow us the capital we need to go after any viable acquisitions as well as explore opportunities within our company to boost revenues in our existing market segments," stated Dr. Bruce Bedrick , CEO of Medbox.  

The company also announced that it is on pace to have its best financial performance quarter in company history in Q1 2013 and is in the process of closing 4 acquisition targets within Q2 2013 that have executed term sheets with Medbox.

About Medbox, Inc: 

Medbox is a leader in the development, sales and service of automated, biometrically controlled dispensing and storage systems for medicine and merchandise. Medbox has offices throughout the world, including New York, Arizona, Connecticut, Massachusetts, Tokyo, London and Toronto, and has their corporate headquarters in Los Angeles.

Medbox provides their patented systems, software and consulting services to pharmacies, dispensaries, urgent care centers, drug rehab clinics, hospitals, prison systems, hospice facilities, and medical groups worldwide.

Medbox, Inc. is a publicly traded company, and is quoted on the OTC Markets, ticker symbol MDBX.

For more information on Medbox, please contact the Medbox Investor Relations Department at (800) 762-1452 or go online to www.medboxinc.com.


'/>"/>
SOURCE Medbox, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Medbox Partners with Bio-Tech Medical Software to Create Nations Safest Prescription Drug and Medical Marijuana Distribution System
2. Medbox, Inc. Comments on Record Trading Day
3. Medbox, Inc. Featured in Multiple Media Stories in Massachusetts and California
4. Medbox, Inc. Releases Demo Video and Collateral Media Concerning How Their Systems Will Be Used in Massachusetts Medical Marijuana Dispensaries
5. Medbox Communicates with Shareholders, Comments on Pending Transition to OTC Bulletin Board, and Announces Appearance on Fox Business News Channel
6. AVT Develops Biometrically Secure Medicine Storage and Retrieval System for Medbox RX
7. Medbox, Inc. Releases 2nd Quarter Financials
8. Medbox Safe Storage and Access Lockers Gaining Popularity
9. Medbox Developing a Patent Pending Wall-Mounted Biometric Kiosk for Storage of Sensitive Medicine Samples and Supplies for Doctors Offices.
10. Medbox, Inc. Announces Top-Tier Rating by Dun & Bradstreet Credibility Corporation
11. RayBiotech, Inc. Executes Neuroscience Biomarker Master Services Agreement with Banner Sun Health Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... ... April 27, 2017 , ... ... and a name change to Fluence Analytics. , Fluence Analytics provides ... polymer and biopharmaceutical manufacturing processes and R&D applications. The company’s patented technologies ...
(Date:4/27/2017)... WASHINGTON , April 27, 2017  Kinexum, a ... science products, today announces the appointment of Thomas ... G. Alexander ("Zan") Fleming, M.D., Kinexum founder, who becomes ... strategic advisor to Kinexum clients. Thomas ... take on the Kinexum mission and lead the firm,s ...
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced ... added to its extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme ... only able to offer NAT screening for blood donors under an Investigational New Drug ...
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, ... platform, has signed a collaborative and sponsored research ... Silvia Muro . The overall goal of ... pharmacodynamics of various 3DNA designs and formulations after ... targeting diseases of the vasculature as well as ...
Breaking Biology Technology: